Original Research
Published on 09 Feb 2022
Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
in Drugs Outcomes Research and Policies

- 4,158 views
- 20 citations